Literature DB >> 27668055

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID： 27668055      PMCID： PMC5013850     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  5 in total

1.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

2.  The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Authors:  Louis P Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh
Journal:  Oncologist       Date:  2013-01-08

3.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

Review 4.  New strategies in the treatment of multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

Review 5.  Multiple myeloma: the bone marrow microenvironment and its relation to treatment.

Authors:  S W Andrews; S Kabrah; J E May; C Donaldson; H R Morse
Journal:  Br J Biomed Sci       Date:  2013       Impact factor: 3.829
  5 in total
  6 in total

1.  Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndrome.

Authors:  Ha Eun Kong; Junghwa Lim; Alexander Linsalata; Yunhee Kang; Indranil Malik; Emily G Allen; Yiqu Cao; Lisa Shubeck; Rich Johnston; Yanting Huang; Yanghong Gu; Xiangxue Guo; Michael E Zwick; Zhaohui Qin; Thomas S Wingo; Jorge Juncos; David L Nelson; Michael P Epstein; David J Cutler; Peter K Todd; Stephanie L Sherman; Stephen T Warren; Peng Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

2.  Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid.

Authors:  Ian W Windsor; Michael J Palte; John C Lukesh; Brian Gold; Katrina T Forest; Ronald T Raines
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

Review 3.  Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.

Authors:  Natasha Mupeta Kaweme; Geoffrey Joseph Changwe; Fuling Zhou
Journal:  Front Med (Lausanne)       Date:  2021-02-25

Review 4.  Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Authors:  Grace Lassiter; Cole Bergeron; Ryan Guedry; Julia Cucarola; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Curr Oncol       Date:  2021-01-21       Impact factor: 3.677

5.  A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.

Authors:  Xue-Hua Ling; Shang-Kwei Wang; Yun-Hsuan Huang; Min-Jay Huang; Chang-Yih Duh
Journal:  Mar Drugs       Date:  2018-10-21       Impact factor: 5.118

6.  Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.

Authors:  Yanan Zhu; Rajiv Ramasawmy; Sean Peter Johnson; Valerie Taylor; Alasdair Gibb; R Barbara Pedley; Nibedita Chattopadhyay; Mark F Lythgoe; Xavier Golay; Daniel Bradley; Simon Walker-Samuel
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.